Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.

Abstract excerpt

Non-small cell lung cancer (NSCLC) frequently metastasizes to the brain in approximately 20-40% of cases. Mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) are common in NSCLC, with the KRASG12C variant accounting for approximately 40% of KRAS-mutant cases. Up to 40% of NSCLC patients harboring the KRASG12C mutation develop brain metastases during follow-up, and a substantial proportion present...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Neoplasms
• Share to Carcinoma, Non-Small-Cell Lung